Pure Global
NCT06404723

The Predictive and Prognostic Values of the Fibrinogen to Albumin Ratio and C-reactive Protien to Albumin Ratio in Systemic Lupus Erythematosus Patients

Sohag University·ClinicalTrials.gov·diagnostic testNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Systemic Lupus Erythematosus
Drug/Device/Intervention
Fibrinogen to albumin Ratio and C-reactive to Albumin Ratio
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Sohag University
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2024
End date
Apr 01, 2025
Enrollment
150 participants
Primary outcome

Fibrinogen/Albumin ratio, C-reactive protein /Albumin ratio

Summary

The aim of the study was to study the predictive value of FAR and CAR in order to provide a
 new predictive biomarkers for the disease activity and prognosis.

ICD-10 classifications
Systemic lupus erythematosusSystemic lupus erythematosus, unspecifiedLupus erythematosusSystemic lupus erythematosus with organ or system involvementOther forms of systemic lupus erythematosus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06404723
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06404723 through Pure Global AI's free database. This phase not specified trial is sponsored by Sohag University and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.